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Abstract
Background: Perturbations to the composition and function of bronchial bacterial communities appear to contribute
to the pathophysiology of asthma. Unraveling the nature and mechanisms of these complex associations will require
large longitudinal studies, for which bronchoscopy is poorly suited. Studies of samples obtained by sputum induction
and nasopharyngeal brushing or lavage have also reported asthma-associated microbiota characteristics. It remains
unknown, however, whether the microbiota detected in these less-invasive sample types reflect the composition of
bronchial microbiota in asthma.
Results: Bacterial microbiota in paired protected bronchial brushings (BB; n = 45), induced sputum (IS; n = 45), oral
wash (OW; n = 45), and nasal brushings (NB; n = 27) from adults with mild atopic asthma (AA), atopy without asthma
(ANA), and healthy controls (HC) were profiled using 16S rRNA gene sequencing. Though microbiota composition
varied with sample type (p < 0.001), compositional similarity was greatest for BB-IS, particularly in AAs and ANAs. The
abundance of genera detected in BB correlated with those detected in IS and OW (r median [IQR] 0.869 [0.748–0.942]
and 0.822 [0.687–0.909] respectively), but not with those in NB (r = 0.004 [− 0.003–0.011]). The number of taxa shared
between IS-BB and NB-BB was greater in AAs than in HCs (p < 0.05) and included taxa previously associated
with asthma.
Of the genera abundant in NB, only Moraxella correlated positively with abundance in BB; specific members of this genus
were shared between the two compartments only in AAs. Relative abundance of Moraxella in NB of AAs correlated
negatively with that of Corynebacterium but positively with markers of eosinophilic inflammation in the blood and BAL
fluid. The genus, Corynebacterium, trended to dominate all NB samples of HCs but only half of AAs (p = 0.07), in whom
abundance of this genus was negatively associated with markers of eosinophilic inflammation.
Conclusions: Induced sputum is superior to nasal brush or oral wash for assessing bronchial microbiota composition in
asthmatic adults. Although compositionally similar to the bronchial microbiota, the microbiota in induced sputum are
distinct, reflecting enrichment of oral bacteria. Specific bacterial genera are shared between the nasal and the bronchial
mucosa which are associated with markers of systemic and bronchial inflammation.
Keywords: Adult asthma, Atopy, Upper airways, Lower airways, Bronchial microbiota, Nasal microbiota, Induced sputum
microbiota, Oral microbiota, Eosinophilic inflammation, Moraxella, Corynebacterium
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Background
A growing body of evidence implicates perturbations
to the composition and function of bronchial bacterial
communities in the pathophysiology of asthma across
a broad breadth of clinical presentations [1–7]; relative enrichment of members of the Proteobacteria,
such as Haemophilus and Neisseria in the lower airways, is a consistent feature of inflammatory airway
disease [1, 3–5, 7]. We confirmed this enrichment in
our recent study of mild atopic asthmatic subjects, in
conjunction with bronchial expansion of the oral
commensals, Fusobacterium and Porphyromonas [3],
whose relative abundance was associated with sputum
eosinophilia. Like most studies of the bronchial
microbiota in asthma, our study relied on the invasive
procedure of bronchoscopy. We used this procedure
to obtain protected bronchial brushings, whereas
others have used it to obtain unprotected brushings
or broncho-alveolar lavage (BAL) for microbial analysis [1, 4]. Taken together, these independent observations have provided tantalizing insights into the
relationships between the bronchial microbiota and
asthma but suggest great complexity, with a highly
heterogeneous microbial community differing across
subjects with distinct phenotypes of asthma and possibly within subjects over time. Unraveling these complex
relationships will likely require longitudinal studies of
large numbers of subjects, but the costs, discomforts, and
expertise required to perform bronchoscopy significantly
limit subject recruitment. The studies done so far have
thus mostly enrolled only adults and have been
cross-sectional in design and small in size.
Correcting these deficiencies will require less invasive
sampling approaches for studying the airway microbiome in asthma. Several studies have reported
asthma-associated differences in bacterial community
composition of sputum samples from asthmatic subjects
[8–11], characterized by expansion of Haemophilus,
Moraxella, and Streptococcus. Enrichments in these
genera have also been described in studies of hypopharyngeal aspirates from children with wheezy respiratory
illness [12], of hypopharyngeal and nasopharyngeal
samples from infants who went on to develop asthma
[13, 14], and in nasal samples of asthmatic children
[15] including those who experienced more severe
rhinovirus infections and related exacerbations of
asthma [14, 16].
The associations of asthma and of asthma exacerbations with perturbations of the bacterial communities in
the nose, nasopharynx, or induced sputum raise questions as to the relationships between the microbiota of
the upper and lower airways. In healthy adults, dispersal
of microorganisms from the oral (but not the nasal)
cavity is considered the dominant source of bronchial
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microbiota [17–20], through naturally occurring microaspiration rather than carry over during sample collection [18]. It remains unclear, however, whether the
bacterial topography of healthy airways is also characteristic of asthmatic airways. It is also unclear how representative the bacterial communities described in
less-invasive sample types are of the composition of
bronchial microbiota in asthma.
To address these questions, we took advantage of protected bronchial brush (BB), induced sputum (IS), oral
wash (OW), and nasal brush (NB) samples obtained in a
subset of a larger cohort of adults in whom the relationships between the bacterial microbiota in BB samples
and disease category (atopy with mild asthma—AAs;
atopy without asthma—ANAs; and neither atopy nor
asthma—HCs) were studied [3]. We anticipated that the
bacterial microbiota detected in the less-invasive sample
types would differ from those found in BB samples, and
we sought to address two main questions in our analysis:
first, to determine which of these samples most closely
resembled protected bronchial brushings in community
composition, and, second, to determine which, if any, of
these samples also revealed known asthma-related taxa
or taxa associated with clinical or inflammatory features
of atopic asthma in our subjects.

Results
Study group characteristics

Atopic asthmatic (AA) subjects in this cohort had
mild well-controlled disease, significantly higher
serum total IgE, blood and sputum eosinophil cell
counts, and were more likely to report a history of allergic rhinitis compared to atopic non-asthmatics
(ANAs) and non-atopic healthy control (HC) subjects
(Table 1 and Additional file 1 Table S1).
The nasal airways harbor less complex bacterial
communities than the lower airways

To determine compositional similarity between less-invasive airway sample types and BBs, we first focused on
alpha diversity indices for the subset of samples (n =
27 pairs) from our larger study cohort [3], for which
NB samples were collected and all four samples were
profiled (NB, IS, OW, and BB; Additional file 1: Table
S2). Comparison of alpha diversity indices across
these paired specimen types showed that the richness
and diversity of the microbiota of BB was significantly
higher than NB, but significantly lower than IS and OW
(Fig. 1a–d). Expanding the comparison of alpha diversity
indices between BB, IS, and OW to the larger subset of
samples (i.e., including subjects from whom NB samples
were not obtained; n = 45; Additional file 1: Table S2),
confirmed that bacterial communities detected in IS
samples were more diverse than both BB and OW

Durack et al. Microbiome (2018) 6:104

Page 3 of 16

Table 1 Study cohort characteristics
Variable

Allergic asthmatics
(AA)
(n = 22)

Allergic non-asthmatics
(ANA)
(n = 12)

Non-allergic non-asthmatics
(HC)
(n = 11)

p value#

Age (yrs)

39 (27–45)

33 (25–47)

28 (26–48)

NS

ACQ score (baseline)*

0.7 (0.3–1.0)

–

–

–

% Male

50%

67%

36%

NS€

68%

50%

72%

NS€

25 (23–30)

27 (21–32)

27 (23–28)

NS

FEV1% predicted pre-Alb

86 (69–97)

98 (91–107)

104 (97–112)

0.001

FEV1% predicted post-Alb¥

99 (83–106)

104 (96–107)

107 (101–121)

0.035

% White
2

BMI (kg/m )
¥

Change in FEV%

9.5 (6.0–15.0)

3.0 (1.0–6.5)

4.0 (1.0–5.0)

< 0.0001

PC20 (methacholine)

1.1 (0.3–2.8)

> 32$

> 32$

< 0.0001

Serum IgE (EU/mL)

169.5 (68.8–313.0)

88.5 (43.5–175.0)

14.0 (5.0–37.0)

< 0.0001

No. of positive sIgE¢

6 (3–9)

4 (2–6)

–

NS&

Allergic rhinitis (%)

55%

25%

0%

0.006€

Blood neutrophils (%)

53.1 (48.0–61.2)

52.8 (51.0–61.8)

58.4 (53.3–63.0)

NS

Blood eosinophils (%)

3.7 (1.9–5.3)

2.0 (1.4–5.0)

1.8 (1.2–3.0)

0.076

Sputum neutrophils (%)

50.8 (30.1–63.6)

34.6 (15.0–44.4)

41.1 (37.7–65.5)

NS

Sputum eosinophils (%)

0.5 (0.0–2.6)

0.1 (0.0–0.5)

0.0 (0.0–0.4)

0.041

BAL GM-CSF (pg/mL)

349 (194–571)

476 (233–840)

154 (125–258)

0.010

BAL IL-6 (pg/mL)

102 (49–185)

160 (67–164)

70 (23–110)

NS

BAL IL-7 (pg/mL)

0.3 (0.3–37.6)

0.3 (0.3–20.5)

0.3 (0.3–0.3)

NS

BAL IL-8 (pg/mL)

1407 (843–3864)

1311 (870–2851)

953 (503–1180)

NS

BAL CXCL11 (pg/mL)

371 (137–628)

801 (421–937)

339 (171–396)

0.036

BAL MIP-1α (pg/mL)

82 (49–174)

114 (74–156)

69 (38–106)

NS

BAL MIP-1β (pg/mL)

317 (200–616)

275 (240–394)

128 (113–350)

0.095

BAL MIP-3α (pg/mL)

390 (162–1668)

411 (242–715)

264 (126–918)

NS

BAL TNF (pg/mL)

70 (17–99)

65 (42–106)

29 (22–76)

NS

BAL IL-1β (pg/mL)

0.04 (0.04–4.2)

0.04 (0.04–7.9)

0.04 (0.04–0.04)

NS

BAL IL-21 (pg/mL)

0.8 (0.04–17.8)

8.3 (0.04–37.1)

0.04 (0.04–3.1)

NS

¥

$

All values are medians (IQR).*ACQ—Asthma Control Questionnaire. Alb—Albuterol. Methacholine challenge was stopped at 32 mg/dL and PC20 for these
subjects was censored. ¢Number of positive specific IgE (sIgE > 0.35 kU/l) from a total of 12 aeroallergens tested by ImmunoCap assay. Statistical significance was
determined using #Kruskal-Wallis, &Mann-Whitney, or €Chi-square test with p values > 0.1 assigned NS; p values <0.05 are highlighted in bold and those trending
towards significance <0.1 are italicized

(Additional file 1: Figure S1a–d). These observations
suggest that the microbiota found in IS is likely sourced
in variable degrees from the upper and lower airways.
In contrast, the nasal airways comprise of less complex
communities than those detected in the bronchi of
adult subjects, findings that are in agreement with
those from other studies [5, 17]. We additionally found
the microbiota of IS to be more diverse than that of
oral wash, indicating that this sample type reflects a
more complex community. Importantly, this relationship in alpha diversity across sample types remained
conserved in samples from AA and HC subjects analyzed independently (Additional file 1: Figure S2a–b).
As reported previously [3], phylogenetic diversity in the
subset of BBs examined in this study (n = 27 and n = 45)

tended to be higher in AAs compared to HC subjects
(Additional file 1: Figure S2a–b). No such trend was
observed in comparison of the other sample types from
the same individuals, nor was a difference in other
alpha-diversity indices found from comparison of AAs
and HCs (data not shown). These findings suggest that
the phylogenetic expansion reported in our earlier study
of mild atopic asthma is confined to protected BB samples; the signature is not detected in other sample types
from our very mild group of asthmatic adults.
Bacterial microbiota in BB, IS, OW, and NB across all
subjects is compositionally distinct

We next assessed the overall phylogenetic community
composition by principal coordinate analysis and found
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Fig. 1 Alpha diversity in the microbiota of different specimen types demonstrating that the upper airway harbors significantly sparser bacterial
communities than the lower airways or the oral cavity. a Bacterial richness as indicated by the total number of taxa detected in each sample
type. b Shannon index of bacterial diversity in each sample type. c Phylogenetic Faith’s index of bacterial diversity in each sample type. d Pielou’s
index of community evenness in each sample type. Statistical significance was determined using Wilcoxon matched-pairs signed rank test

that microbiota composition co-varied with sample
type (Fig. 2a; unweighted UniFrac; LME p < 0.001).
Bronchial microbiota was compositionally distinct from
all other sample types (Additional file 1: Figure S3a–c; unweighted UniFrac; LME p < 0.001), although intra-subject
paired distance between BB and other sample types was
significantly shorter for OW than NB (Fig. 2b and
Additional file 1: Figure S4a), suggesting less compositional similarity between the microbiota of the bronchi
and the nasal cavity. Bacterial microbiota membership
(Fig. 2c) and to a lesser extent community structure
(Additional file 1: Figure S4a–b) in BB were more similar
to those detected in IS samples than between BB and NB
or OW samples.
Using paired samples from 45 participants, we demonstrate that although the membership of the microbiota
in IS resembled OW more closely than BB (unweighted
UniFrac; Fig. 2c), this was not the case for the community structure (weighted UniFrac; Additional file 1:
Figure S4b). Overall, bacterial communities detected in
IS were distinct from OW samples (Additional file 1:
Figure S3d; unweighted UniFrac LME p = 0.019), indicating that IS microbiota are not simply mirroring OW
bacterial communities. To determine whether this observation was consistent across the three subject groups,
we examined the mean paired distance between BB-IS
and BB-OW across AAs, ANAs, and HCs. Mean paired
distance to BB was shorter for paired IS than OW in
AAs (unweighted UniFrac; Fig. 2d and weighted
UniFrac; Additional file 1: Figure S4c), indicating that
the resemblance in bacterial membership of IS to BB
was greater in AA than in HC subjects (Fig. 2e).
Community membership in IS samples of ANAs was
also more similar to BB than those detected in OW
(unweighted UniFrac; Fig. 2d) though this relationship
did not extend to the overall community structure

(weighted UniFrac; Additional file 1: Figure S4c). However, in the HC subjects, mean paired distance between
BB-OW and BB-IS was indistinguishable (Fig. 2d and
Additional file 1: Figure S4c). Unfortunately, likely due
to the small number of HCs in whom NB samples were
collected, confounded further by greater dissimilarity in
community composition between NB and BB, we found
no difference in the BB-NB paired distance between AAs
and HC subjects (Additional file 1: Figure S4d–e).
Taxonomic architecture in IS samples more closely
resembles that of the bronchial microbiota in asthmatic
than in healthy adults

Taxonomic comparison across samples (Fig. 2f ) indicated that the overall relative abundance of bacterial
genera detected in BB samples correlated more strongly
with those detected in IS and OW (Pearson r median
[IQR] = 0.869 [0.748–0.942] and r = 0.822 [0.687–0.909]
respectively Additional file 1: Table S3) than with those
present in the NB samples (r = 0.004 [− 0.003–0.011];
Additional file 1: Table S3 and Figure S5a). Consistent
with our earlier observation of a shorter mean paired
distance between BB-IS compared to BB-OW, taxonomic composition in BB correlated more strongly with
those in IS than OW (Additional file 1: Figure S5b) in
the AAs but not ANA or HC subjects (Additional file 1:
Figure S5c–e). Together, these findings suggest that
asthma and to a lesser extent atopy may be associated
with heightened predisposition of the airways to bacterial colonization resulting in communities which are less
like those colonizing the oral cavity.
The bronchial microbiota was predominantly colonized by Prevotella, Actinomyces, and to a lesser extent
Porphyromonas and Streptococcus (Fig. 3), a pattern similar
to that observed for IS samples. Specifically, the relative
abundance of Prevotella, Actinomyces, Corynebacterium,

Durack et al. Microbiome (2018) 6:104
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Fig. 2 Compositionally lower airway microbiota is more similar to the oral than nasal cavity. a Principal coordinate analysis (unweighted UniFrac)
shows compositional dissimilarity between paired samples (linear mixed-effects model, p < 0.0001). b Mean intra-subject paired distance to BB
shows that the NB microbiota are most distinct from BB (Wilcoxon matched-pairs signed rank test; Whiskers extend to 95% confidence interval).
c Shorter mean intra-subject paired distance between IS and BB compared to OW and BB, suggests that the IS microbiota are more representative of
BB than OW is of BB (Wilcoxon matched-pairs signed rank test; Whiskers extend to 95% confidence interval). d Shorter mean intra-subject paired
distance is observed between BB and IS compared to OW in AAs and ANAs but not HCs (Paired t test). e Shorter mean intra-subject paired distance
between IS and BB in AAs compared to HCs (Welch’s corrected t test; Whiskers extend to 95% confidence interval) suggests that IS microbiota are
more representative of BB in asthmatic subjects. f Summary of the relative abundance of taxa identified in paired samples (n = 27) shows NB as being
the most compositionally distinct. Bacterial taxonomic classification is shown at a family (genus) level

and Staphylococcus was indistinguishable between paired
BB and IS samples (Fig. 3) but differed between these two
samples and the OW. Furthermore, the overall relative
abundance of Prevotella and Corynebacterium correlated
between BB and IS paired samples (Additional file 1:
Table S4) as did those of Porphyromonas, Streptococcus,
and Leptotrichia. Although the relative abundance of all
highly prevalent genera examined (present at ≥ 3% in
either of the samples) was distinct between BB and OW
samples, a significant correlation was observed in the
relative abundance of Leptotrichia, Porphyromonas,
Corynebacterium, and Streptococcus (Additional file 1:
Table S4). It should be noted, though, that the relative
abundance of all highly prevalent genera examined
(present at ≥ 3% in either of the samples) also correlated between IS and OW (Additional file 1: Table S4),
attesting to the unsurprising similarity in community
composition between these sample types. In contrast, NB
samples were predominantly colonized by Corynebacterium
followed by Staphylococcus, Streptococcus, Alloiococcus,
and Moraxella (Fig. 3). Notably, the relative abundance of

only Moraxella correlated strongly between BB and NB
samples without also showing a correlation between BB-IS
and BB-OW (Additional file 1: Table S4). No significant difference in the relative abundance of the above genera were
observed in any of the four samples between AAs and HC
subjects, although that of a Staphylococcus trended to be
higher in NBs of AAs (Additional file 1: Figure S6a), This
enrichment was confirmed at operational taxonomic unit
(OTU) level in the NB of AA subjects (Additional file 1:
Figure S6b).
Next, we evaluated the number of specific OTUs per
participant in a larger number of samples (BB, IS, and
OW n = 45 pairs), which were exclusive or shared across
sample types in our three subject groups (Fig. 4a). We
found that a large and similar number of OTUs was
shared between all three sample types in all subject
groups (Kruskal-Wallis p = 0.48), but that the median
number of OTUs shared between IS-BB but not between
OW-BB samples was higher in AAs and ANAs compared to HC subjects (Fig. 4b). Interestingly, within the
AAs, the number of IS-BB-shared OTUs was higher
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Fig. 3 Distribution of the relative abundance for most prevalent genera (present at ≥ 3% in any one of the samples) in the four paired (n = 27)
specimen types, illustrates the dissimilarity in bacterial composition of NB compared to other samples. Significance was determined using
Wilcoxon matched-pairs signed rank test (p > 0.05 not shown)

than those shared between OW-BB paired samples
(Fig. 4b). Additionally, phylogenetic diversity for taxa
shared between IS-BB samples trended to be higher in
AAs and ANAs compared to HCs (Fig. 4c), which was
not observed for taxa shared between OW-BB samples
(Mann Whitney; p > 0.2). The OTUs predominantly
shared (in at least 20% of subjects) between BB-IS samples in AAs included members of Prevotella and a number of other genera previously reported to be associated
with asthma, specifically Haemophilus, Fusobacterium,
and Neisseria [3], which were not shared at the same
frequency between BB-IS samples in the HC subjects

(Fig. 4d). Overall, these findings suggest that though
significant differences are apparent between all non-invasive sample types and protected bronchial brush bacterial
communities, IS microbiota more closely resemble that of
BB than do those in OW and NB samples in atopic asthmatic and atopic non-asthmatic adults. This is not to say
that taxa detected in IS represented all those detected in
the BB, since a number of taxa detected in each sample included sample-specific members of Fusobacterium, Neisseria, Aggregatibacter, Streptococcus, and Prevotella
(Additional file 1: Figure S5f). Additionally, among taxa
identified in BB but not IS were members of genera whose
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Fig. 4 A greater number of operational taxonomic units (OTUs) was exclusively shared between IS-BB in AAs compared to HC subjects and
included taxa previously associated with asthma. a Number of OTUs associated with specific sample type in AAs, ANAs, and HC subjects. Values
are shown as a median (IQR). b A greater number of OTUs was shared exclusively (in at least 20% of subjects) between IS and BB in AAs and
ANAs compared to HCs, which was greater than those shared in BB-OW (Welch’s corrected t test and &Wilcoxon matched-pairs signed rank test;
p > 0.2 not shown). c Faith’s Phylogenetic diversity (PD) of taxa shared between paired IS-BB samples trended to be higher in AAs and ANAs
compared to HCs (Mann Whitney test; p > 0.2 not shown). d Frequency distribution of specific genera (present in at least 20% of participants for
each group) for OTUs shared exclusively between IS-BB was distinct in AAs and HCs and included known asthma-associated taxa (Chi-square test;
p > 0.05 not shown)

enrichment has previously been associated with asthma
[1, 3, 7, 9], such as Pseudomonas, Sphingomonas, and
Moraxella; this was true as well for Lactobacillus whose
depletion has been similarly associated with asthma [3].
Conversely, among taxa detected in IS that were not detected in BB were specific members of Haemophilus and
Porphyromonas (Additional file 1: Figure S5f), whose
enrichment has been reported in asthmatic airways in
previous studies.
Bronchial microbiota comprise taxa shared with both the
oral and to a lesser extent the nasal cavity and include a
suite of asthma-associated bacterial genera

Considering that the bronchial microbiota in healthy
subjects has been reported to simply reflect dispersal
from the oral cavity [17–22], we next thought to evaluate the contribution of the oral and nasal bacterial
communities to the bronchial microbiota in our subjects.
Although bronchial microbiota was found to be
compositionally distinct from both the OW and NB, we

hypothesized that a proportion of taxa detected in BB
samples would also be detected in paired OW and NB
samples from each individual. Indeed, we identified a
number of specific OTUs that were shared with BB samples, significantly greater for OW samples (median/IQR
290/230–348; Fig. 5a) than for NB samples (median/IQR
26/13–48). Taxa also found in OW represented a large
proportion (Fig. 5b; median/IQR 61/57–67%) of the total
taxa detected in BB samples, a dramatically larger proportion than for the taxa shared between BB-NB samples (median/IQR 6/3–11%). Similarly, the phylogenetic
diversity of the taxa shared between OW-BB (Additional
file 1: Figure S7a; median/IQR 22/17–24) accounted for
a larger proportion of the overall phylogenetic diversity
of BB samples (Additional file 1: Figure S7b; median/
IQR 66/63–76%), compared to the much smaller contribution to the diversity of taxa shared with NB (median/
IQR 15/9–20%). Asthmatic subjects shared a greater
number of OTUs between NB and BB samples than did
HCs (Fig. 5c), but this was not the case for the number
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Fig. 5 A proportion of all the taxa detected in the BB is shared with paired NB and OW samples, with each compartment contributing distinct
taxa to the bronchial community. a The number of taxa shared with BB is higher for OW compared to NB (Wilcoxon matched-pairs signed rank
test). b Richness of taxa shared represents a larger proportion of the overall richness detected in BB sample for paired OW compared to
NB (Wilcoxon matched-pairs signed rank). c Richness of the shared taxa between paired BB and NB was greater in AAs compared to HCs
(&Mann-Whitney test). d Distribution of specific taxa shared with paired BB is distinct between NB and OW samples in AAs. (Genera identified
in at least 20% of subjects in the same sample type; Statistical significance between OW and NB genera was determined using Fisher’s exact
test where ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05)

of OW-BB-shared OTUs, although the phylogenetic
diversity of the NB-BB-shared taxa was similar for AAs
and HCs (Mann-Whitney, p > 0.20). These results indicate that the oral cavity may serve as a source of bacteria
for the lower airway microbiota in both healthy and
asthmatic subjects, accounting for over 60% of the bronchial microbiota complexity. A novel observation of this
study is that the nasal airway may also share microbiota members with the bronchial microbiota in
adults and that in AA and ANA subjects more
taxa are shared between the two compartments.
Additionally, we show that OW and NB share distinct
bacterial genera with the bronchial microbiota, since
a comparison of the taxa shared between each of

these niches and the bronchial microbiota was found
to have no significant phylogenetic correlation (Mantel
test; r = − 0.031, p = 0.69).
Of the known asthma-associated bacteria, a number
were identified among those shared between BB and
either or both nasal and oral compartments in AAs. As
expected, the taxa shared between BB-OW samples
included oral commensal genera such as Fusobacterium,
Porphyromonas, and Neisseria (Fig. 5d), whereas Streptococcus, Corynebacterium, Staphylococcus, and to a lesser
extent Haemophilus were among taxa detected with
equal frequency as shared between BB-NB and BB-OW
(Fig. 5d). It is important to note, however, that HCs also
exhibited the presence of these genera among taxa
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shared between BB and either or both NB and OW samples (Additional file 1: Figure S7c). Taxa exclusively
shared between bronchial and nasal microbiota included
members of Pseudomonas and Moraxella in AAs
(Fig. 5d). Importantly, Moraxella was not detected
among the taxa shared between NB and BB of healthy
subjects (Additional file 1: Figure S7c). Collectively,
these findings indicate that the nasal taxa shared with
bronchial airways in asthma may be few in number but
great in importance, as they include bacterial genera previously associated with asthma in adults [1, 7] and asthma
exacerbation in children [14–16].
Nasal microbiota of asthmatics is associated with clinical
and immunological features of allergic inflammation

Recent studies of adult airway microbiota in respiratory
disease have described specific patterns of bacterial
colonization with distinct dominant genera in both the
upper [23] and lower [24] airway compartments,
differentially associated with divergent clinical outcomes.
Accordingly, we assessed the distribution of bacterial
genera dominating each of the paired samples and found
that Prevotella was most frequently found to dominate
BB and IS (Additional file 1: Figure S6c) and that there
was no significant difference in its prevalence across
these sample types (21/27 and 23/27, respectively; Fisher’s exact p = 0.73; Additional file 1: Figure S6c). In contrast, this genus dominated OWs with lower frequency
(12/27) and did not dominate any of the NB samples
(0/27; Fisher’s exact p = 0.024 and p < 0.0001, respectively; Additional file 1: Figure S6c). The microbiota
of NBs also differed dramatically in the frequency
with which Corynebacterium dominated these samples
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(19/27 Additional file 1: Figure S6c), further highlighting
niche specificity in bacterial microbiota of the nasal airways. Our analysis of the frequency of Prevotella dominance in the four sample types from AAs and HC subjects
showed them not to differ (Additional file 1: Figure S6d),
and the consistency between BB and IS samples was observed in both groups. There was, however, a difference in
the frequency of dominance by Corynebacterium in NB
samples, which was found in all HCs but in only half of
the AA subjects (Fig. 6a; Fisher’s exact p = 0.07). Possibly
because of the small sample size and the mildness of the
asthma of our subjects, we did not detect differences in
the frequency distribution of other dominant genera
between AAs and HC subjects, although we note that
Moraxella-dominated communities in NB samples
were detected only in asthmatic subjects (3/18 AAs,
Additional file 1: Figure S6c).
In light of these observations, we enquired whether
the relative abundance of the prevalent bacterial genera
in the AAs was associated with a number of clinical and
immunological features characteristic of the disease. Indeed, the relative abundance of Actinomyces in both BB
and OW samples was inversely associated with serum
IgE levels, as well as BAL neutrophil counts and G-CSF
levels, respectively (Table 2). No significant associations
were found between the inflammatory and clinical parameters examined and the relative abundance of the
prevalent genera in IS samples, likely due to the complexity of the microbiota detected in this specimen type.
Surprisingly, the most associations with features of
atopic asthma was observed with bacterial genera detected in the nasal airways (Table 2) and included those
previously implicated in asthma in pediatric studies [14].

Fig. 6 Nasal microbiota in asthmatic patients are associated with markers of systemic and bronchial inflammation. a Frequency distribution of
Corynebacterium dominant communities in NB samples was lower in AAs (n = 18) compared to HC (n = 6) subjects (Fisher’s exact test). b The
relative abundance of Corynebacterium in NB samples in AAs correlated negatively with a number of inflammatory markers of atopic asthma
(Spearman correlation). c The relative abundance of Moraxella in NB samples in AAs correlated positively with a number of inflammatory markers
of atopic asthma (Spearman correlation)
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Table 2 Significant associations between the relative abundance
of prevalent bacteria genera (present at ≥3% in either of the
samples) and clinical and inflammatory parameters in AAs
Variables

rho§

p value

BH p value&

Relative abundance of Actinomyces in BB
Serum IgE (IU/mL)

− 0.57

0.014

0.191

BAL neutrophils (%)

− 0.63

0.007

0.182

Relative abundance of Actinomyces in OW
Serum IgE (IU/mL)

− 0.64

0.005

0.082

BAL GM-CSF

− 0.63

0.006

0.082

0.006

0.164

Relative abundance of Alloiococcus in NB
PC20

0.62

Relative abundance of Corynebacterium in NB
Blood eosinophils (cells/mL)

− 0.49

0.041

0.183

BAL eosinophils (%)

− 0.51

0.036

0.183

BAL IL-6

− 0.61

0.009

0.154

BAL IL-7

− 0.54

0.021

0.154

BAL IL-21

− 0.56

0.016

0.154

BAL MIP1-a

− 0.47

0.048

0.187

0.55

0.017

0.152

Sputum eosinophils (%)

0.64

0.007

0.100

BAL eosinophils (%)

0.69

0.002

0.063

BAL ITAC

0.50

0.036

0.188

BAL TNF

0.49

0.042

0.188

Relative abundance of Moraxella in NB
Blood eosinophils (absolute)

Relative abundance of Streptococcus in NB
Blood eosinophils (cells/mL)

0.55

0.017

0.198

BAL IL-7

0.53

0.022

0.198

Analysis performed using Spearman correlation coefficient. &p values were
FDR corrected for multiple comparisons using Benjamini Hochberg method,
with values ≤ 0.2 considered significant
§

For instance, the relative abundance of Alloiococcus
positively correlated with PC20 (i.e., with lower bronchial
reactivity) and that of Corynebacterium negatively correlated with a number of systemic and bronchial inflammatory markers including BAL eosinophil counts, IL-6,
IL-7, and IL-21 levels (Table 2 and Fig. 6b). In contrast,
the relative abundance of Moraxella and Streptococcus
correlated positively with systemic and lower airway
eosinophilia (Table 2 and Fig. 6c) and bronchial
pro-inflammatory cytokines including TNF and IL-7, respectively. We did not detect a correlation between the
relative abundance of these two genera (Spearman,
p > 0.20), but both were negatively associated with the
relative abundance of Corynebacterium (Spearman
rho = − 0.51 and − 0.53, respectively, p = 0.030).
Additionally, asthmatic subjects whose nasal microbiota
was dominated by Corynebacterium exhibited significantly
lower levels of pro-inflammatory BAL cytokines,

specifically IL-6, IL-7, and IL-21 (Additional file 1: Table
S5) compared to subjects exhibiting nasal microbiota
dominated by other bacterial genera. Nasal microbiota of
the Corynebacterium-dominated subgroup of asthmatic
subjects were enriched for specific taxa belonging to Corynebacterium, Streptococcus, and Lactobacillus genera and
were highly depleted for members of Moraxella, Neisseriaceae, Streptococcus, Staphylococcus, and Haemophilus
compared to asthma subjects whose nasal microbiota was
dominated by non-Corynebacterium genera (Additional
file 1: Table S6). Whilst the bronchial microbiota in the
same subjects was enriched for specific but unique members of Microbacteriaceae, Lactobacillus, and Leptotrichia
and depleted for a number of taxa including Streptococcus,
Treponema, Fusobacterium, and Neisseria (Additional
file 1: Table S7). Thus, it appears that bronchial microbiota
in asthmatics whose nasal microbiota is dominated by
non-Corynebacterium bacterial genera are enriched for
asthma-associated taxa, which may explain the elevated
levels of pro-inflammatory cytokines in these subjects.
However, apart from the observation that nasal Corynebacterium dominance of asthmatic subjects was more frequently observed in males (80%, Fisher’s exact p = 0.06;
Additional file 1: Table S5), we were limited by a small
sample size in this study to identify any other patient characteristics associated with this microbiological signature.
Nevertheless, our observations suggest that predominant colonization of the nasal airways with members of
Corynebacterium may serve as a biomarker for dampened inflammation associated with atopic asthma and
are in agreement with prior observations of infant
nasopharyngeal colonization with these genera being
associated with lower risk for acute respiratory illness
[14, 25], a risk factor for asthma development later in
life [26–28]. Collectively, these findings suggest that the
nasal microbiota in adult asthmatics, although distinct
from bronchial bacterial communities, may prove useful
biomarkers of bronchial and systemic inflammation associated with atopic asthma.

Discussion
In this study, we aimed to address the compositional
similarity between the bacterial microbiota detected in
samples obtained by minimally invasive sampling approaches (nasal brushing, oral wash, sputum induction)
to those detected in protected bronchial brushings, focusing on adults with mild, corticosteroid-naïve atopic
asthma and adults without atopy or asthma. Our findings
confirm niche specificity of microbiota in adult airways
but indicate that the architecture of the bacterial communities in induced sputum, particularly in asthmatic subjects, resembles that in protected bronchial brushings
more closely than do those in oral or nasal samples. Of
the sampling methods examined, our observations
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collectively support the use of IS for inferring lower airway
microbial community composition in asthmatic individuals, recognizing that IS microbiota may provide an incomplete picture of the bronchial microbiota, and
inaccurately bias the microbiota composition to reflect
oral taxa enrichment, especially in very mild airway disease, as in our cohort. However, our analyses by multiple
approaches consistently found evidence in asthmatic subjects of greater similarity in IS and BB bacterial microbiota compared to non-asthmatic subjects. Further, while
the bacterial communities found in the nasal mucosa were
distinct from those in the bronchial mucosa, their composition was associated with markers of systemic and
bronchial inflammation clinically relevant to asthma. Another novel observation we report in this study is that
nasal airways are a potential source of distinct bacterial
taxa for lower airways in adults, and that this inoculum is
richer in atopic asthmatic subjects.
Although our findings provide evidence in support of
using less-invasive sampling methods to study the airway
microbiota in larger numbers of asthmatic patients,
important limitations of these findings must be acknowledged. The number of subjects from our cohort who
had all paired sample types available for analysis was
relatively small, especially a paucity of NB samples from
atopic subjects without asthma, an important control
group to compare against subjects with atopic asthma.
Thus, the observation of a richer shared microbiota
composition between NB and BB samples in asthmatic
than in healthy subjects could reflect associations with
atopic status and immune responses. Also, a relatively
constricted scope of asthma phenotype was captured in
our cohort who all had mild, corticosteroid-naïve atopic
asthma. The similarities and dissimilarities we quantified
between upper airway and bronchial samples in bacterial
microbiota composition may or may not hold true in
other asthma phenotypes or with worsened disease activity. Our analysis also focused only on adult subjects,
and it is possible that findings may differ in infants and
young children due to differences in anatomical distance
between upper and lower airway compartments. A major
strength of this study is the standardized collection and
analysis of paired upper and lower airway sample types,
all of which were collected either on the same day (NB,
OW and BB at bronchoscopy visit) or within 2 weeks
(IS) prior to the bronchoscopy.
Our findings confirm that different compartments of
the airways harbor compositionally distinct microbiota
in patients with asthma, as they do in healthy adults
[17]. They further reveal the bacterial communities colonizing the nasal cavity to be significantly scarcer than
those colonizing the lower airways. That we should
find the microbial composition of induced sputum to
differ overall from bronchial brush is not surprising,
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given that an earlier study reported distinct differences
in the microbial communities detected in BAL and
brush obtained from the same subjects [1]. We expected comparison of the induced sputum and protected bronchial brushes collected in our study to
reveal dissimilarities, considering the unavoidable contamination of bronchial secretions by saliva during the
process of sputum collection, as well as the difference
in spatial topography of the airways sampled by either
method. Indeed, we found the microbiota of induced
sputum to be compositionally most similar to oral
wash but still to resemble the bronchial brush microbiota more closely than did oral wash or nasal brush
samples. The taxonomic architecture of induced sputum samples resembled that of the bronchial brush
samples, particularly in atopic subjects, and the taxa
shared between the two sample types included those
previously reported to be associated with asthma, including members of Haemophilus, Fusobacterium, and
Neisseria [1, 3–5, 7]. These observations suggest that
the bacterial communities in induced sputum, although
distinct from those of the bronchial mucosa, capture useful aspects of the latter in asthma. This finding is encouraging for future mechanism-oriented studies aimed at
elucidating the contribution of the airway microbiome to
asthma heterogeneity, enabling expansion of studies to include larger cohorts of patients and the ability to study patients repeatedly over time.
Nasal colonization with S. aureus has previously been
reported as a risk factor for asthma diagnosis in children
and young adults [29], while Staphylococcus-derived products have been observed to directly induce
pro-inflammatory Th2 inflammation in human nasal epithelium [30] and exacerbate allergic airway inflammation
in experimental model of asthma in mice [31]. Our observation of enrichment of Staphylococcus in the nasal microbiota of atopic asthmatics in our cohort further supports a
possible role for this pathobiont in asthma. Further, despite our finding that nasal and bronchial microbiota are
compositionally distinct in asthmatic as well as healthy
[17] adults, we identified a suite of bacterial taxa shared
between these two compartments that accounted for over
15% of the bronchial phylogenetic diversity in our atopic
asthma subjects. Although this contribution of the nasal
compartment is dwarfed by the contribution of taxa from
the oral cavity, both compartments contribute distinct and
important asthma-associated taxa to the lower airways in
adult asthma, as has been shown in children with chronic
lung disease [32]. In particular, we show that the relative
abundance of Moraxella correlates positively between
paired nasal and bronchial brush samples, and members
of this genus are among the taxa shared between the two
compartments in some of our asthmatic but in none of
the healthy subjects. Intriguingly, the relative abundance
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of nasal Moraxella was positively associated with systemic
and airway eosinophil counts, suggesting associations with
allergic inflammation, as well as with asthma-associated
[33, 34] pro-inflammatory chemokine CXCL11 and TNF
levels in bronchial lavage fluid. Increased expression of
nasal epithelial TNF has also been reported in children
and adolescents with asthma whose nasal microbiome
was enriched for M. catarrhalis [35].
This association of nasal Moraxella with inflammatory
cells and cytokines in our asthmatic subjects contrasted
with our findings related to detection of Corynebacterium
in nasal brushings. Corynebacterium was detected as a
dominant genus in the nasal samples from all healthy subjects, but in only half of our asthmatic subjects, in whom
the abundance of this genus was negatively associated
with the presence of Moraxella and Streptococcus in
nasal brushes and of eosinophils in the blood and of
asthma-associated [30, 33] inflammatory cytokines in
BAL fluid. Previous findings from a number of pediatric
studies have shown differences in nasal microbiota to
be related to differences in asthma-related outcomes
[12–16, 25], suggesting that the microbiota of the nasal
airways may be a biomarker of asthma risk in children.
Of particular interest in this context is the finding of an
inverse relationship in the abundance of Corynebacterum and both Moraxella [25, 36] and Streptococcus
[36–38] in the nasal microbiota of young children and
inverse association with respiratory health [14, 25],
which appear to be sustained in adult airways of asthmatic subjects. The mechanisms driving these antagonistic interactions may involve commensal bacteria directly
inhibiting outgrowth of a pathobiont, as was shown for
commensal Corynebacterium’s inhibition of S. pneumoniae growth in- vitro [38], but much more work is needed
to explore these relationships and their subsequent associations with host immune function. At the least, our
findings suggest that additional studies of the nasal microbiota associations to asthma-related inflammation, phenotype, clinical course, or response to therapy are warranted.

Conclusion
We conclude that in adults, induced sputum is superior
to nasal brush or oral wash for studying bronchial
microbiota in asthma. Although compositionally similar,
the microbiota in induced sputum are distinct from
bronchial microbiota in reflecting enrichment of oral
bacterial taxa. Although the nasal microbiota was highly
distinct from that of the oral or bronchial compartments, the abundance of specific bacterial genera in
nasal brushes from asthmatic subjects (Corynebacerium
and Moraxella) was associated with abundance or depletion in bronchial brushes of genera previously reported as
associated with asthma, and further to be associated with
markers of systemic and bronchial inflammation. Future
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studies designed to elucidate bacterial mechanisms contributing to the pathophysiology of asthmatic airway inflammation may therefore benefit from parallel sampling
of lower and upper airway compartments.

Methods
Study population and sample collection

The study cohort consisted of a subset of subjects enrolled in the NHLBI AsthmaNet microbiome study
NCT01537133 [3] and included 22 atopic asthmatics
(AA), 12 atopic non-asthmatics (ANA) and 11 non-atopic
healthy control subjects (HC) whose characteristics are
summarized in Table 1 and Additional file 1: Table S1.
Atopy was defined by serologic evidence (> 0.35 kU/l)
of sensitivity to ≥ 1 of 12 aeroallergens (specific IgE by
ImmunoCap; Thermo-Scientific). Asthma was confirmed by measurement of airway responsiveness
(methacholine PC20 ≤ 8 mg/mL or FEV1 improvement
≥ 12% post-albuterol). Allergic inflammation in asthmatic subjects was assessed by measurement of circulating and sputum inflammatory cells and BAL levels of
inflammatory cytokines [33]. At enrollment, asthmatics
had been clinically stable for 3 months, without the use
of a controller medication in the preceding 6 months.
Exclusion criteria included a history of smoking, respiratory infection within 6 weeks or antibiotic use
within 3 months of enrollment. Each subject signed informed consent approved by their center’s IRB; an
NHLBI-appointed Data Safety Monitoring Board (DSMB)
oversaw the study conduct.
Samples processed for microbiota analysis were collected across nine clinical centers and included 45 paired
protected bronchial brushings (BB), oral wash (OW) and
induced sputum (IS) samples. In subset of 27 of these
45 subjects, intranasal brushings (NB) were also collected (Additional file 1: Table S2). The distribution of
samples did not vary significantly across clinical centers
(Chi-square; p > 0.10). IS samples were collected as previously described [39] within a 2-week window (median
8 [IQR 8–10] days) from the date of bronchoscopy and
those with > 80% squamous epithelial cell counts were
excluded from the study. All samples intended for
microbial analysis were stored in RNAprotect Saliva
Reagent (QIAgen) at − 80 °C until processing.
BAL cytokine multiplex testing

Bronchoalveolar lavage (BAL) supernatants collected
during bronchoscopy visit were concentrated by applying
4 mL of sample to Amicon Ultra-4 Centrifugal Filter Unit
tubes (Millipore) following centrifugation at 4000g for
40 min at 4 °C. Concentrated BAL fluid was assayed using
a MILLIPLEX MAP human high sensitivity T cell panel
21-plex immunology multiplex assay (Millipore) with
antibody-coated beads for detection of Fractalkine, TNF,
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MIP-3α, MIP-1β, MIP-1α, ITAC, IL-23, IL-21, IL-17A,
IL-13, IL-12 (p70), IL-10, IL-8, IL-7, IL-6, IL-5, IL-4, IL-2,
IL-1β, IFNγ, and GM-CSF. Standards and experimental
samples were tested in duplicate. Results were acquired
on a Labscan 200 analyzer (Luminex) using Bio-Plex manager software 6.1 (Bio-Rad). A 5-point logistic regression
curve was used to calculate the concentration from the
fluorescence intensity of the bead measurements. Samples
that were below the level of detection were assigned
one-half the lowest detectable value for that analyte. Out
of the 21 targeted cytokines, only 11 had detectable levels
in at least 4 (i.e., 20%) subjects; these were included in the
comparisons with the microbiological data.
Nucleic acid extraction and 16S rRNA-based sequencing

Nucleic acids were extracted as previously described [7]
using a modified bead-beating protocol and the AllPrep
kit (QIAgen). The variable region 4 (V4) of the 16S
rRNA gene was amplified using 515F/806R primer combination as previously described [40, 41]. Amplicons
were purified using SPRI beads (Beckman Coulter) or
in the presence of multiple bands, gel-extracted with
a QIAgen Gel Extraction kit (QIAgen), analyzed on
Bioanalyzer (Aligent), and quantified using the Qubit
HS dsDNA kit (Invitrogen). Only samples with amplicons ≥ 10 ng were sequenced. Blank control DNA extracts were also amplified, bead purified, and sequenced.
Samples with sufficient amplicon were pooled at 50 ng per
sample, with a blank control per 30–35 samples. The barcoded, pooled library was quantified using the Qubit HS
dsDNA kit (Invitrogen), denatured and 5pM was loaded
onto the Illumina MiSeq cartridge (V3) in combination
with a 15% (v/v) of denatured 12.5pM PhiX for sequencing.
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Diversity and UniFrac distances on OTU table multiply
rarefied [48] to 26,185 sequences per sample.
Statistical analysis

All statistical analyses were performed as indicated in
QIIME, R environment or using PRISM software. Statistical tests used were selected based on the outcome of
Shapiro-Wilk’s normality test coupled with a graphical approach. Wilcoxon matched-pairs rank test was used for
comparison between correlated sample types. Welch’s corrected t test, or Mann-Whitney test and Chi-square or
Fisher’s exact test where appropriate were used to determine significant differences in comparisons between independent study groups. Spearman correlation was used to
test for an association between the relative abundance of
bacterial genera in paired sample types and immunological and clinical parameters in AA subjects. Ordination
was visualized using principal coordinate analysis (PCoA)
on unweighted UniFrac distance matrix and plotted using
Emperor [49]. Significant differences in beta-diversity between paired samples were calculated on unweighted UniFrac PC1 coordinates (as a response variable) using Linear
mixed effects (LME) model ([50] using lmerTest package
in R). Three-model approach (Poisson, negative binomial,
and zero-inflated negative binomial mixed-effect models)
corrected [51] for multiple testing (q < 0.10) as previously
described [52] was used to determine specific OTUs in
NBs or BB which differed in relative abundance between
groups. Mantel test [53] based on unweighted UniFrac
distance was used to compare phylogenetic contribution
of nasal and oral compartments to BB microbiota based
on OTUs shared between paired samples.

Additional file
Sequence data processing and quality control

Paired-end sequences were combined using FLASh version
1.2.7 [42]. Sequence analysis was performed using the
Quantitative Insights into Microbial Ecology (QIIME) pipeline [43]. Raw sequences were de-multiplexed by barcode
and quality filtered by removing low-quality sequences. Sequences with three or more consecutive bases with a Q
score < 30 were truncated and discarded if the length was
less than 75% of the original 250 bp read length. Sequences
were aligned using PyNAST [44], and operational taxonomic units (OTUs) were picked at 97% sequence identity
using UCLUST [45] against the Greengenes database [46].
Reads that failed to hit the reference sequence collection
were retained and clustered de novo. PyNAST-aligned sequences were chimera checked using ChimeraSlayer and
putative chimeras as well as OTUs identified in negative
controls (Additional file 1: Table S8) were removed from
the working OTU table. A phylogenetic tree was built using
FastTree [47] and used to compute Faith’s Phylogenetic

Additional file 1: Supplemental information includes Figures S1-7 and
Tables S1-8. (DOCX 10754 kb)
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